There are 2789 resources available
325P - Trends of primary tumor resection in de novo metastatic breast cancer: The experience of a Mexican center
Presenter: Fabio Gonzalez-Mondellini
Session: ePoster Display
326P - National multicentre retrospective study on metastatic breast cancer patients to characterize long responder under eribulin: LORELINE study
Presenter: Marie Ange Mouret Reynier
Session: ePoster Display
327P - Predictors of progression-free survival in patients with metastatic breast cancer receiving palbociclib with letrozole
Presenter: Roya Behrouzi
Session: ePoster Display
328TiP - Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09
Presenter: Sara Tolaney
Session: ePoster Display
330TiP - Trastuzumab deruxtecan (T-DXd; DS-8201) in HER2-positive (HER2+) and HER2-low expressing (HER-LE) metastatic breast cancer (MBC) with brain metastases (BM) and/or leptomeningeal carcinomatosis (LMC): DEBBRAH
Presenter: Marta Vaz Batista
Session: ePoster Display
331TiP - HER2CLIMB-04: Phase II trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases
Presenter: Lisa Carey
Session: ePoster Display
333TiP - AMEERA-1: Phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) PIK3CA-mutated advanced breast cancer
Presenter: Mario Campone
Session: ePoster Display